C-<i>erb</i>B2/HER2 in Human Gliomas, Medulloblastomas, and Meningiomas

Waage, Ingunn Syversen; Vreim, Ingeborg; Torp, Sverre Helge

doi:10.1177/1066896913492196

Cited by 15 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HER2 expression in meningiomas ranged considerably from 2% to 100% without clear relation between expression and tumor grade. [13] In the present study, HER2 expression was higher in Grade I meningiomas than in Grade II/III meningiomas in contrast to the typically increased expression in higher grade tumor.…”

Section: Discussioncontrasting

confidence: 54%

“…[14] In future strategies, HER2 has a significant role in diagnostic and targeted therapy in intracranial tumors. [13] In our study, HER2/neu positivity was noted in 73% of meningiomas. Slightly higher HER2/neu immunopositivity was seen in males compared to females.…”

Section: Discussionsupporting

confidence: 53%

“…[8,9] Some studies have also noted the HER2/neu expression in astrocytoma, oligodendroglioma, anaplastic astrocytoma, glioblastoma multiforme, medulloblastoma, and pituitary adenoma. [10][11][12][13] According to Waage et al, [13] HER2 expression in neurons and meningeal cells is variable. However, glial cells are generally HER2 negative, but reactive astrocytes in gliotic tissue may be positive.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Telugu

Chowhan

Rukmangadha

et al. 2016

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

Background:Meningiomas are common slow-growing primary central nervous system tumors that arise from the meningothelial cells of the arachnoid and spinal cord. Human epidermal growth factor receptor 2 (HER2) or HER2/neu (also known as c-erbB2) is a 185-kD transmembrane glycoprotein with tyrosine kinase activity expressed in meningiomas and various other tumors. It can be used in targeted therapy for HER2/neu positive meningiomas.Aim:To correlate the expression of HER2/neu protein in meningiomas with gender, location, histological subtypes, and grade.Materials and Methods:It was 3½ years prospective (March 2010–October 2011) and retrospective (May 2008–February 2010) study of histopathologically diagnosed intracranial and intraspinal meningiomas. Clinical details of all the cases were noted from the computerized hospital information system. Immunohistochemistry for HER2/neu protein was performed along with scoring. Statistical analysis was done using Chi-square test to look for any association of HER2/neu with gender, location, grade, and various histological subtypes of meningiomas at 5% level of significance.Results:A total of 100 cases of meningiomas were found during the study period. Of which, 80 were Grade I, 18 were Grade II, and 2 were Grade III meningiomas as per the World Health Organization 2007 criteria. The female-male ratio was 1.9:1 and the mean age was 47.8 years. HER2/neu protein was expressed in 75% of Grade I and 72.2% of Grade II and none of Grade III meningiomas. About 72.7% brain invasive meningiomas showed HER2/neu immunopositivity.Conclusion:HER2/neu protein was expressed in 73% of meningiomas. Statistically significant difference of HER2/neu expression was not seen between females and males of Grade I and Grade II/III meningiomas, intracranial and spinal tumors, Grade I and Grade II/III cases, and various histological subtypes of meningiomas.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Telugu

Chowhan

Rukmangadha

et al. 2016

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

show abstract

“…Expression of HER2 has previously been investigated in human meningiomas with ambiguous results [ 9 ]. Low [ 10 , 11 ], moderate [ 12 , 13 ], and large [ 14 – 19 ] proportions of immunoreactive tumors have been reported.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of ErbB2/HER2 in human meningiomas

et al. 2018

View full text Add to dashboard Cite

IntroductionAmong clinical challenges regarding human meningiomas is their propensity to recur even in cases with benign histology. Reliable biomarkers that can identify these cases are therefore highly desired. ErbB2/HER2 status is important in the medical management of patients with various human malignancies, whereas its clinical relevance in human meningiomas is ambiguous. For this reason, we wanted to investigate the expression of intra- and extracellular domains of ErbB2/HER2 as well as the level of activated receptor in these tumors. Further, we wanted to elucidate any clinicopathological associations to antibody expression and if gene amplification was present.MethodsIn total, 186 human meningiomas of all malignancy grades were included in the study, 163 of these were in tissue microarrays (TMA). Antibody expression was assessed by means of immunohistochemistry (IHC) and gene amplification by fluorescence in situ hybridization (FISH).ResultsAll cases were immunoreactive with antibodies targeting the intracellular domain, whereas about 48% and 11% were positive with antibodies against the extracellular domain and against the activated receptor, respectively. Normal meninges were not immunoreactive. There were no relations to malignancy grade, and only the activated receptor was significantly correlated with increased risk for recurrence or death (time to recurrence: HR 1.568, CI (1.153 to 2.132), p = 0.004). No gene amplification was found.ConclusionErbB2/HER2 is generally upregulated in human meningiomas, but in an activated state only in a few cases. Only the activated receptor is associated with poorer prognosis, a link that needs further investigations.

show abstract

“…Since the association between HER-2 gene amplification and disease prognosis was demonstrated (10,11), overexpression of the gene has been observed in a variety of primary human carcinoma, including breast cancer (12,13), gastric cancer (14,15), gastroesophageal adenocarcinomas (16) and mucinous epithelial ovarian cancer (17). Initially, HER-2 was found to be upregulated in meningioma (18)(19)(20)(21). Subsequently, several studies have provided evidence that Her-2 is important in meningiomas (19,20).…”

Section: Introductionmentioning

confidence: 99%

Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility

Wang

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Meningiomas are common types of intracranial tumor. Invasive and malignant meningiomas present a significant therapeutic challenge due to high rates of recurrence and invasion. Understanding the molecular mechanism of invasion may assist in designing novel therapeutic approaches and improving patient survival rates. The HER‑2 gene has been demonstrated to be a useful predictor of tumor aggression, which promotes the survival and growth of cancer cells through the mitogen‑activated protein kinase and/or phosphatidylinositol 3‑kinase (PI3K)/AKT pathway. Until now, few studies have investigated the associateion between meningiomas and the expression of HER‑2, and the significance of HER‑2 in meningiomas remains to be elucidated. The present study aimed to investigate the effects of the HER‑2 gene on the biological behaviors of human malignant meningioma cells. The results demonstrated that downregulation of the expression of HER‑2 by small interfering RNA in human meningioma cells significantly inhibited cell motility and proliferation, led to cell cycle arrest at the G0/G1‑phase and increased early apoptosis. By contrast, the overexpression of HER‑2 group resulted in meningioma cell invasion, migration and proliferation being significantly enhanced, cell cycle was promoted at the G1/S‑phase and early apoptosis was decreased. Accordingly, the inhibition of HER‑2 also prevented the protein expression of PI3K and phosphorylated AKT. The results demonstrated that regulation of the HER‑2 gene can affect the proliferation, apoptosis, invasion and metastasis abilities of human meningioma cells in vitro. Furthermore, PI3K/AKT may contribute to the carcinogenesis and development of human meningiomas in combination with HER-2.

show abstract

C-erbB2/HER2 in Human Gliomas, Medulloblastomas, and Meningiomas

Cited by 15 publications

References 73 publications

Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study

Prognostic value of ErbB2/HER2 in human meningiomas

Role of HER-2 activity in the regulation of malignant meningioma cell proliferation and motility

Contact Info

Product

Resources

About